Ascentage Pharma to Participate in Three Upcoming Investor Conferences
Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $48.00 price target on the stock.